US Patent

US8301238 — Two-part electrotransport device

Formulation · Assigned to Alza Corp · Expires 2031-09-30 · 5y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a two-part electrotransport device for delivering therapeutic agents, such as fentanyl hydrochloride, through electrodes and reservoirs.

USPTO Abstract

A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.

Drugs covered by this patent

Patent Metadata

Patent number
US8301238
Jurisdiction
US
Classification
Formulation
Expires
2031-09-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Alza Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.